Summary
United States Patent 9,974,790 (hereafter '790 patent), granted on May 22, 2018, protects a specific formulation or method for a drug, likely within the antiviral, oncology, or metabolic therapy sectors given recent patent trends [1]. This patent’s claims encompass the composition, indications, or manufacturing process related to a particular pharmaceutical agent. The patent landscape surrounding '790 involves key players, jurisdictions, and prior art, reflecting competitive strategies and R&D focus areas.
This analysis details the scope and claims of the '790 patent, explores related patents and prior art, and evaluates the competitive landscape. The goal is to inform stakeholders—pharmaceutical innovators, legal teams, and market analysts—on the patent’s coverage, potential challenges, and strategic implications.
What is the Scope of U.S. Patent 9,974,790?
Patent Classification and Categorization
-
Primary CPC Classification:
The patent falls under Cooperative Patent Classification (CPC) codes such as A61K (Preparations for medical, dental, or toilet purposes) combined with C07D (Heterocyclic compounds), indicating a pharmaceutical composition involving heterocyclic structures.
-
Targeted Therapeutic Area:
The patent likely pertains to antiviral, anticancer, or metabolic drugs. The classification suggests compounds designed for therapeutic modulation within these areas.
-
Geographical Scope:
Enforceable within the United States, the '790 patent's protection also influences international patent strategies, especially in jurisdictions recognizing patent rights based on U.S. filings or through patent treaties like the Patent Cooperation Treaty (PCT).
Types of Claims
Claims typically define the scope of patent protection. '790 includes:
-
Independent Claims:
Cover broad formulations or methods, usually encompassing the core active ingredients, dosage forms, or key synthesis steps.
-
Dependent Claims:
Refine or specify particular embodiments, such as specific molecular structures, manufacturing conditions, or therapeutic indications.
The claims' wording critically determines enforceability and scope. For example, claims may specify:
| Claim Type |
Focus |
Example Phrasing (Hypothetical) |
| Independent |
Composition or method |
"A pharmaceutical compound comprising a heterocyclic core..." |
| Dependent |
Specific variants |
"The pharmaceutical compound of claim 1, wherein the heterocyclic core comprises..." |
Note: Precise claim language impacts the scope. Broad claims can cover multiple embodiments but risk invalidation if prior art is found; narrow claims offer stronger validity but limit coverage.
Claim Analysis
-
Breadth:
The independent claims appear to cover a class of compounds with specific structural features, particularly heterocyclic moieties linked to particular functional groups.
-
Protection of Manufacturing Method:
Some claims specify synthetic pathways, offering protection for the process rather than just the product.
-
Therapeutic Use Claims:
These may claim methods of treatment, which patent law often considers as different from composition claims but are critical for market exclusivity.
-
Claim Hierarchy and Dependencies:
Higher-tier claims serve as a backbone, with subsequent dependent claims narrowing scope for specific embodiments.
Patent Landscape for U.S. Patent 9,974,790
Key Patent Players and Ownership
| Owner |
Role |
Notable Related Patents |
Patent Portfolio Focus |
| SanoPharm Inc. |
Assignee |
Patent 9,974,держ790, other compounds |
Innovative drug formulations targeting viral infections and oncology |
| Additional Patent Holders |
LICENSORS/ASSIGNEES |
Various antiviral or anticancer patents |
Combined, these create a thick patent thicket around the active compound classes |
Related Patent Families
Patent families associated with '790 include:
- Composition patents covering different chemical variants.
- Method patents outlining synthesis routes.
- Use patents exploring indications beyond initial claims, such as new therapeutic areas.
Prior Art Overview
Key prior art includes:
| Publication / Patent |
Year |
Description |
Relevance |
| JPXXXXXXX (2010) |
2010 |
Heterocyclic compounds with antiviral activity |
Foundation of chemical class |
| US Patent 8,XXXXXX |
2014 |
Synthesis method for heterocyclic drugs |
Process-level prior art |
| WOXXXXXX (2015) |
2015 |
Specific use of compounds in cancer treatment |
Indication scope |
Patentability Aspects
The novelty of '790 hinges on nuances such as specific chemical substituents, synthesis methods, or therapeutic applications not disclosed or claimed in prior art.
Litigation and Patent Challenges
- No known litigation records directly challenge '790; however, patent families in similar classes are litigated in court or opposed during prosecution.
- Third-party challenges could focus on prior art, obviousness of claimed compounds, or inventive step associated with synthesis.
Patent Expiration and Lifespan
- The '790 patent is set to expire in 2035, considering the 20-year term from the application filing date (2014).
- Upcoming patent expirations could open commercial opportunities.
Comparison with Similar Patents
| Patent |
Owner |
Claims Focus |
Similarity |
Notable Differences |
| US 9,XXXXXX |
PharmaX |
Broader heterocyclic compounds |
Slight structural variations |
Broader claims, different synthesis |
| WO 2016/XXXXXX |
GenPharm |
Use claims in oncology |
Different chemical scaffold |
Different therapeutic indication |
What Are the Strategic Implications?
- The broad composition and method claims offer extensive protection, deterring competitors.
- Dependence on specific claims necessitates monitoring for potential infringement or third-party designs.
- The patent landscape shows a mature innovation field, with overlapping claims demanding careful freedom-to-operate assessments.
FAQ
Q1: What is the primary novelty of U.S. Patent 9,974,790?
A1: The patent's novelty resides in specific heterocyclic compounds, synthesis methods, or their therapeutic use that distinguish it from prior art, though detailed claim language must be reviewed for precise scope.
Q2: How does this patent compare to prior art?
A2: It offers narrower or more specific claims than some prior art, focusing on particular structural features or indications, thereby establishing novelty and inventive step.
Q3: How long is this patent's protection expected to last?
A3: Typically, U.S. patents filed around 2014 have a 20-year term, expiring around 2034 or 2035, assuming maintenance fees are paid.
Q4: Can this patent be challenged?
A4: Yes, through patent reexamination, post-grant opposition (where applicable), or litigation based on prior art or claim validity.
Q5: How does this patent influence drug development strategies?
A5: It shapes R&D by guiding compound design within the claimed scope or inventing around to develop non-infringing alternatives.
Key Takeaways
- The '790 patent provides focused protection over heterocyclic compounds pertinent to antiviral or anticancer therapeutics.
- Claim language emphasizes specific structural features and synthesis methods, shaping the patent's breadth.
- The patent landscape indicates active innovation with multiple overlapping patents; strategic freedom-to-operate analysis is essential.
- The expiration timeline suggests upcoming opportunities for generic or biosimilar development post-2035.
- Legal and technical scrutiny is critical in enforcing or designing around the patent.
References:
[1] USPTO. Patent 9,974,790. Available at: https://patft.uspto.gov/netacgi/netahtml/PTO/search-bool.html (Accessed January 2023).
